Budesonide – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:08 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Budesonide – CRI Report https://www.cri-report.com 32 32 Investigation Report on Chinese Budesonide Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinese-budesonide-market-2021-2025/ Sat, 10 Apr 2021 06:25:31 +0000 https://www.cri-report.com/?post_type=product&p=10971 According to CRI market research, the sales of Budesonide increased from 2016 to 2019, with a CAGR of approximately 9.26%. However, the sales of Budesonide decreased by 29.30% in 2020 because of the COVID-19 epidemic.

The post Investigation Report on Chinese Budesonide Market 2021-2025 first appeared on CRI Report.

]]> Budesonide is an adrenal cortex hormone medicine. It is available in different forms, such as inhalant, nasal spray, and so on. The inhalation form is used to treat asthma and chronic obstructive pulmonary disease. The nasal spray form is used to treat allergic rhinitis and nasal polyps.

In the Chinese pharmaceutical market, Budesonide mainly has three dosage forms, including inhalation suspension, gas (powder) aerosol, and nasal spray. The most common one is Budesonide inhalation suspension, which was first developed and produced by AstraZeneca. In 2001, Budesonide entered the Chinese market. By 2020, the main manufacturers of Budesonide in China are AstraZeneca, Chia Tai Tianqing, Synmosa Biopharma, and Lunan.

According to CRI market research, the sales of Budesonide increased from 2016 to 2019, with a CAGR of approximately 9.26%. However, the sales of Budesonide decreased by 29.30% in 2020 because of the COVID-19 epidemic. The sales revenue in 2020 was approximately CNY1.1 billion. With the improvement of the epidemic situation, CRI predicts that the sales of Budesonide in China will have a recovery growth in the short run.

In recent years, the respiratory sector in the Chinese pharmaceutical market has a growth trend, mainly due to the heavy burden of asthma patients, the high smoking rate, and the deepening of aging. Thus, CRI analyzes that in addition to the recovery growth, the sales of Budesonide will increase in 2021-2025 as the market expands.

Topics Covered:
-The impact of COVID-19 on China’s budesonide market
– Sales value and volume of China’s budesonide 2016-2020
– Competitive landscape of China’s budesonide market
– Prices of budesonide in China
– Prices of budesonide in China by regions and manufacturers
– Analysis on factors affecting the development of China’s budesonide market
– Prospect of China’s budesonide market from 2021 to 2025

The post Investigation Report on Chinese Budesonide Market 2021-2025 first appeared on CRI Report.

]]> Sample of Investigation Report on China Budesonide Market, 2018-2022 https://www.cri-report.com/sample-of-investigation-report-on-china-budesonide-market-2018-2022/ Fri, 04 Jan 2019 06:42:23 +0000 https://www.cri-report.com/?post_type=product&p=6812 This is a free sample of Investigation Report on China Budesonide Market, 2018-2022

The post Sample of Investigation Report on China Budesonide Market, 2018-2022 first appeared on CRI Report.

]]> This is a free sample of

Investigation Report on China Budesonide Market, 2018-2022

The post Sample of Investigation Report on China Budesonide Market, 2018-2022 first appeared on CRI Report.

]]> Investigation Report on China Budesonide Market, 2018-2022 https://www.cri-report.com/investigation-report-on-china-budesonide-market-2018-2022/ Fri, 17 Aug 2018 09:04:44 +0000 https://www.cri-report.com/product/import-placeholder-for-1806295/ Its annual sales increased from approximately CNY 100 million in 2007 to approximately CNY 1.2 billion in 2017 with the CAGR from 2007 to 2017 up to 27.7%.

The post Investigation Report on China Budesonide Market, 2018-2022 first appeared on CRI Report.

]]> Description
Every year, nearly 300 million people in China, including over 50 million cough patients, get infected with respiratory diseases. It is estimated that the number of asthma patients in China has exceeded 20 million. Inhaled corticosteroids are suitable for the long-term treatment of bronchial asthma and can avoid all kinds of adverse reactions caused by systemic use of corticosteroids. At present, the main inhaled corticosteroids used in clinical practice are Budesonide, Fluticasone and Beclomethasone.
In the 1990s, Budesonide was successfully developed by AstraZeneca to be used for the treatment of non-corticosteroid dependent or corticosteroid-dependent bronchial asthma and chronic obstructive pulmonary disease. In Jun. 1997, Budesonide aerosol was approved by the FDA.
In 1994, China approved the import of Budesonide. In 1995, Astra (Wuxi) Pharmaceutical was approved to manufacture and sell Budesonide in China. Budesonide has been developing rapidly since it entered the Chinese market. Its annual sales increased from approximately CNY 100 million in 2007 to approximately CNY 1.2 billion in 2017 with the CAGR from 2007 to 2017 up to 27.7%. There is a high demand for Budesonide in China. The majority of Budesonide currently sold on the market are manufactured by AstraZeneca, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical Co., Ltd., Orion Pharma and Shanghai Sine Pharmaceutical Laboratories Co., Ltd. In terms of sales, AstraZeneca has the highest market share, accounting for more than 90% of the Chinese market in 2017.
Owing to the aggravating environmental pollution and ageing population, China will see a rising incidence of respiratory diseases from 2018 to 2012, which will lead to an ever-expanding Budesonide market.

Topics Covered
-Development history of Budesonide in China
-Size of Chinese Budesonide market
-Market share of major Budesonide manufacturers in China
-Market share of various dosage forms of Budesonide in China
-Budesonide prices on the Chinese market
-Prospects of Chinese Budesonide Market, 2018-2022

 

The post Investigation Report on China Budesonide Market, 2018-2022 first appeared on CRI Report.

]]>